sulfamethoxazole has been researched along with Cystic Fibrosis of Pancreas in 25 studies
Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208)
sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To utilize T cells from sulfamethoxazole (SMX) hypersensitive patients with cystic fibrosis to examine the HLA molecules that interact with nitroso SMX (SMX-NO)-derived antigens." | 7.81 | HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. ( Alfirevic, A; Baker, DM; Faulkner, L; Naisbitt, DJ; Ogese, MO; Park, BK; Peckham, D; Pirmohamed, M; Saide, K; Sette, A; Whitaker, P, 2015) |
| "To compare mechanisms of antigen presentation and characterize the phenotype and function of T cells from sulfamethoxazole-hypersensitive patients with and without cystic fibrosis." | 7.77 | Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. ( Callan, H; Castrejon, L; El-Ghaiesh, S; Elsheikh, A; Farrell, J; Lavergne, SN; Monshi, M; Naisbitt, DJ; Park, BK; Peckham, D; Pichler, WJ; Whitaker, P, 2011) |
| "Sulfamethoxazole (SMX) is an important antibiotic in the management of patients with cystic fibrosis, but allergic reactions may develop thus restricting therapy." | 7.76 | Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. ( Conway, S; Lavergne, SN; Naisbitt, DJ; Park, BK; Peckham, D; Whitaker, P, 2010) |
| "Single-point sulfamethoxazole acetylation activity in blood cells obtained from patients with cystic fibrosis (n = 6) and control subjects (n = 7) who had previously participated in our in vivo study was determined." | 7.69 | Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. ( Hutabarat, RM; Smith, AL; Unadkat, JD, 1994) |
| "The disposition of sulfamethoxazole and trimethoprim, after constant rate intravenous administration (10 mg/kg/hr sulfamethoxazole and 2 mg/kg/hr trimethoprim for 1 hour), was investigated in adult patients with cystic fibrosis (n = 7) and in age-matched healthy subjects (control subjects, n = 8)." | 7.68 | Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ( Hutabarat, RM; McNamara, S; Ramsey, B; Sahajwalla, C; Smith, AL; Unadkat, JD, 1991) |
| "The first-dose and steady-state pharmacokinetics of trimethoprim and sulfamethoxazole were determined in 14 patients with cystic fibrosis." | 7.67 | Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. ( Bertino, JS; Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1984) |
| "During a 1-year period, the prevalence of thymidine-dependent (TD) Staphylococcus aureus in patients at two geographically distinct cystic fibrosis (CF) centers was determined." | 7.67 | Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. ( Gage, PA; Gilligan, PH; Muszynski, MJ; Wait, KR; Welch, DF, 1987) |
| "To utilize T cells from sulfamethoxazole (SMX) hypersensitive patients with cystic fibrosis to examine the HLA molecules that interact with nitroso SMX (SMX-NO)-derived antigens." | 3.81 | HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis. ( Alfirevic, A; Baker, DM; Faulkner, L; Naisbitt, DJ; Ogese, MO; Park, BK; Peckham, D; Pirmohamed, M; Saide, K; Sette, A; Whitaker, P, 2015) |
| "To compare mechanisms of antigen presentation and characterize the phenotype and function of T cells from sulfamethoxazole-hypersensitive patients with and without cystic fibrosis." | 3.77 | Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. ( Callan, H; Castrejon, L; El-Ghaiesh, S; Elsheikh, A; Farrell, J; Lavergne, SN; Monshi, M; Naisbitt, DJ; Park, BK; Peckham, D; Pichler, WJ; Whitaker, P, 2011) |
| "Sulfamethoxazole (SMX) is an important antibiotic in the management of patients with cystic fibrosis, but allergic reactions may develop thus restricting therapy." | 3.76 | Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis. ( Conway, S; Lavergne, SN; Naisbitt, DJ; Park, BK; Peckham, D; Whitaker, P, 2010) |
| "Single-point sulfamethoxazole acetylation activity in blood cells obtained from patients with cystic fibrosis (n = 6) and control subjects (n = 7) who had previously participated in our in vivo study was determined." | 3.69 | Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes. ( Hutabarat, RM; Smith, AL; Unadkat, JD, 1994) |
| "The disposition of sulfamethoxazole and trimethoprim, after constant rate intravenous administration (10 mg/kg/hr sulfamethoxazole and 2 mg/kg/hr trimethoprim for 1 hour), was investigated in adult patients with cystic fibrosis (n = 7) and in age-matched healthy subjects (control subjects, n = 8)." | 3.68 | Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim. ( Hutabarat, RM; McNamara, S; Ramsey, B; Sahajwalla, C; Smith, AL; Unadkat, JD, 1991) |
| "The first-dose and steady-state pharmacokinetics of trimethoprim and sulfamethoxazole were determined in 14 patients with cystic fibrosis." | 3.67 | Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis. ( Bertino, JS; Blumer, JL; Myers, CM; Reed, MD; Stern, RC; Yamashita, TS, 1984) |
| "During a 1-year period, the prevalence of thymidine-dependent (TD) Staphylococcus aureus in patients at two geographically distinct cystic fibrosis (CF) centers was determined." | 3.67 | Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis. ( Gage, PA; Gilligan, PH; Muszynski, MJ; Wait, KR; Welch, DF, 1987) |
| " The data also provide evidence that accumulation of toxic reactive metabolites could be an important component in the cascade of events leading to the development of DHRs in CF patients." | 1.91 | Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk. ( Abuzgaia, AM; Elzagallaai, AA; Mullowney, T; Rieder, MJ, 2023) |
| "The same applies for mucoviscidosis, in which P." | 1.26 | [Therapy of chronic respiratory tract infections in children, including mucoviscidosis (author's transl)]. ( Adam, D, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (56.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, WJ | 1 |
| Goeckeler-Fried, JL | 1 |
| Havasi, V | 1 |
| Chiang, A | 1 |
| Rowe, SM | 1 |
| Plyler, ZE | 1 |
| Hong, JS | 1 |
| Mazur, M | 1 |
| Piazza, GA | 1 |
| Keeton, AB | 1 |
| White, EL | 1 |
| Rasmussen, L | 1 |
| Weissman, AM | 1 |
| Denny, RA | 1 |
| Brodsky, JL | 1 |
| Sorscher, EJ | 1 |
| Abuzgaia, AM | 1 |
| Elzagallaai, AA | 1 |
| Mullowney, T | 1 |
| Rieder, MJ | 1 |
| Van Dalem, A | 1 |
| Herpol, M | 1 |
| Echahidi, F | 1 |
| Peeters, C | 1 |
| Wybo, I | 1 |
| De Wachter, E | 1 |
| Vandamme, P | 1 |
| Piérard, D | 1 |
| Ogese, MO | 1 |
| Saide, K | 1 |
| Faulkner, L | 1 |
| Whitaker, P | 3 |
| Peckham, D | 3 |
| Alfirevic, A | 1 |
| Baker, DM | 1 |
| Sette, A | 1 |
| Pirmohamed, M | 1 |
| Park, BK | 3 |
| Naisbitt, DJ | 3 |
| Lavergne, SN | 2 |
| Conway, S | 1 |
| Elsheikh, A | 1 |
| Castrejon, L | 1 |
| Monshi, M | 1 |
| Callan, H | 1 |
| El-Ghaiesh, S | 1 |
| Farrell, J | 1 |
| Pichler, WJ | 1 |
| Marks, MI | 1 |
| Gold, R | 1 |
| Jin, E | 1 |
| Levison, H | 1 |
| Isles, A | 1 |
| Fleming, PC | 1 |
| Reed, MD | 1 |
| Stern, RC | 1 |
| Bertino, JS | 1 |
| Myers, CM | 1 |
| Yamashita, TS | 1 |
| Blumer, JL | 1 |
| Huang, NN | 2 |
| Schidlow, DV | 1 |
| Palmer, JJ | 1 |
| Antonelli, M | 1 |
| De Angelis, M | 1 |
| Bravo, E | 1 |
| Lorusso, G | 1 |
| Ascalone, V | 1 |
| Cribb, AE | 1 |
| Tsui, B | 1 |
| Isbrucker, R | 1 |
| Michael, RT | 1 |
| Gillespie, CT | 1 |
| Brown-Bonomo, J | 1 |
| Barrett, P | 1 |
| Levatte, T | 1 |
| Renton, KW | 1 |
| Hutabarat, RM | 2 |
| Smith, AL | 2 |
| Unadkat, JD | 2 |
| Kearns, GL | 1 |
| Risch, A | 1 |
| Smelt, V | 1 |
| Lane, D | 1 |
| Stanley, L | 1 |
| van der Slot, W | 1 |
| Ward, A | 1 |
| Sim, E | 1 |
| Adam, D | 1 |
| Hughes, DT | 1 |
| Pines, A | 1 |
| Percival, A | 1 |
| Stille, W | 1 |
| Quietzsch, J | 1 |
| Siegert, E | 1 |
| Günther, J | 1 |
| Parsons, RL | 1 |
| Paddock, GM | 1 |
| Sahajwalla, C | 1 |
| McNamara, S | 1 |
| Ramsey, B | 1 |
| Kuriyama, S | 1 |
| Panosian, C | 1 |
| Lapointe, JR | 1 |
| Bourget, C | 1 |
| Lafleur, L | 1 |
| Lagacé, J | 1 |
| Montplaisir, S | 1 |
| Gilligan, PH | 1 |
| Gage, PA | 1 |
| Welch, DF | 1 |
| Muszynski, MJ | 1 |
| Wait, KR | 1 |
| Rawal, BD | 1 |
| McKay, G | 1 |
| Blackhall, MI | 1 |
3 reviews available for sulfamethoxazole and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Antibiotics in pediatric respiratory diseases.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cephalosporins; Child; Chloramphenicol; Cystic Fibrosis; Emp | 1980 |
Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
Topics: Bile; Biotransformation; Child; Child, Preschool; Cystic Fibrosis; Fleroxacin; Humans; Liver; Liver | 1993 |
Respiratory pharmacology. Antibiotics. II. Aminoglycosides, polymyxins, vancomycin, trimethoprim-sulfamethoxazole, and pentamidine.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cystic Fibrosis; Drug Combinations; Drug Resistance, Microbi | 1986 |
2 trials available for sulfamethoxazole and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Assessment of arylamine N-acetyltransferase (NAT1) activity in mononuclear leukocytes of cystic fibrosis patients.
Topics: 4-Aminobenzoic Acid; Acetylation; Adolescent; Adult; Arylamine N-Acetyltransferase; Centrifugation, | 1995 |
Arylamine N-acetyltransferase in erythrocytes of cystic fibrosis patients.
Topics: Adolescent; Adult; Alleles; Anti-Infective Agents; Arylamine N-Acetyltransferase; Cystic Fibrosis; E | 1996 |
20 other studies available for sulfamethoxazole and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regu | 2016 |
Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Drug Hypersensitivity; Humans; Lymphocytes; Sulfamethoxazole | 2023 |
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Burkholderia cepacia complex; Ceftazidime; Cephalospori | 2018 |
HLA-DQ allele-restricted activation of nitroso sulfamethoxazole-specific CD4-positive T lymphocytes from patients with cystic fibrosis.
Topics: Alleles; CD4-Positive T-Lymphocytes; Cell Proliferation; Cystic Fibrosis; Drug Hypersensitivity; Fem | 2015 |
Drug metabolite-specific lymphocyte responses in sulfamethoxazole allergic patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Infective Agents; Cystic Fibrosis; Drug Hypersensitivity; Female; Humans; Hy | 2010 |
Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Antigen Presentation; Antigen-Presenting Cells; Case-Control Studies; Cell Pr | 2011 |
Treatment of cystic fibrosis with trimethoprim-sulfamethoxazole.
Topics: Cystic Fibrosis; Drug Combinations; Humans; Sulfamethoxazole; Trimethoprim; Trimethoprim, Sulfametho | 1984 |
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
Topics: Adolescent; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Therapy, Combinati | 1983 |
Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis.
Topics: Adolescent; Adult; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Combinations; Drug Synerg | 1984 |
[Absorption of orally-administered cotrimoxazole in patients with cystic fibrosis].
Topics: Child; Child, Preschool; Cystic Fibrosis; Drug Combinations; Humans; Intestinal Absorption; Sulfamet | 1982 |
Disposition of drugs in cystic fibrosis. VII. Acetylation of sulfamethoxazole in blood cells: in vitro-in vivo correlation and characterization of its kinetics of acetylation in lymphocytes.
Topics: Acetylation; Arylamine N-Acetyltransferase; Chromatography, High Pressure Liquid; Cystic Fibrosis; E | 1994 |
[Therapy of chronic respiratory tract infections in children, including mucoviscidosis (author's transl)].
Topics: Cephalosporins; Child; Child, Preschool; Cystic Fibrosis; Drug Combinations; Humans; Infant; Infant, | 1979 |
Round table discussion--treatment of lower respiratory tract infections with co-trimoxazole.
Topics: Bronchiectasis; Bronchitis; Chronic Disease; Cystic Fibrosis; Drug Combinations; Humans; Lung Absces | 1979 |
[Multilobular biliary liver cirrhosis as a purely hepatic form of mucoviscidosis].
Topics: Child; Cholangitis; Cholecystitis; Cystic Fibrosis; Drug Combinations; Humans; Liver Cirrhosis; Male | 1979 |
The use of new antibiotic agents for chronic pulmonary disease.
Topics: Agammaglobulinemia; Aminoglycosides; Anti-Bacterial Agents; Asthma; Bacterial Infections; Cephalospo | 1978 |
Absorption of two antibacterial drugs, cephalexin and co-trimoxazole, in malabsorption syndromes.
Topics: Celiac Disease; Cephalexin; Cholestyramine Resin; Crohn Disease; Cystic Fibrosis; Diverticulum; Drug | 1975 |
Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim.
Topics: Adult; Chromatography, High Pressure Liquid; Cystic Fibrosis; Female; Humans; Male; Metabolic Cleara | 1991 |
Mucoid and pigmentation characters can be suppressed by non-anti-Pseudomonas aeruginosa antibiotics in cystic fibrosis: a report of promising preliminary results.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Doxycycline; Drug Combinations; Humans; Leucomycins; Pigment | 1988 |
Prevalence of thymidine-dependent Staphylococcus aureus in patients with cystic fibrosis.
Topics: Culture Media; Cystic Fibrosis; Drug Combinations; Humans; Respiratory System; Staphylococcus aureus | 1987 |
Inhibition of Pseudomonas aeruginosa by ascorbic acid acting singly and in combination with antimicrobials: in-vitro and in-vivo studies.
Topics: Adolescent; Animals; Anti-Bacterial Agents; Ascorbic Acid; Child; Cystic Fibrosis; Drug Combinations | 1974 |